DNA methylation biomarker panels for differentiating various liver adenocarcinomas, including hepatocellular carcinoma, cholangiocarcinoma, colorectal liver metastases and pancreatic adenocarcinoma liver metastases
The cancer-specific methylation biomarker panels exhibit high sensitivities, specificities and diagnostic accuracies and enable differentiation between primary and metastatic adenocarcinomas of the liver using methylation-specific dPCR. High concordance was achieved between MS-HRM, dPCR and bioinformatic data, demonstrating the successful translation of bioinformatically identified methylation biomarkers from the Illumina Infinium HumanMethylation450 BeadChip (HM450) and lllumina MethylationEPIC BeadChip (EPIC) platforms to the simpler MS-HRM and dPCR platforms.
Authors
- Branislava Ranković (ORCID: https://orcid.org/0000-0001-8642-9809)
- Nina Hauptman (ORCID: https://orcid.org/0000-0002-7575-7716)
- Tina Draškovič (ORCID: https://orcid.org/0000-0002-2425-5855)
- Nina Zidar (ORCID: https://orcid.org/0000-0001-6866-3220)
Institutions
- University of Ljubljana (SI)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1186/s13148-024-01766-z
- Citations
- 5
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Javna Agencija za Raziskovalno Dejavnost RS